NCT07084168

Brief Summary

This pilot study aims to estimate rates of genetic testing in patients with ovarian and endometrial cancer before and after the implementation of educational videos about genetic testing. Subjects will be asked to view one of three videos relevant to their cancer diagnosis and genetic testing, and have the option to complete a brief satisfaction survey. A chart review to evaluate rates of genetic testing ordered and referrals placed to Genetics before and after the implementation of the videos will be conducted. Up to 15-20% of ovarian cancer and 3-5% of endometrial cancer is due to inherited genetic mutation. Given this association, the National Comprehensive Cancer Network (NCCN) recommends genetic counseling and testing for all individuals with a diagnosis of ovarian cancer and endometrial cancer. Some challenges to obtaining genetic counseling and testing include missed identification and referral of eligible patients by providers, lack of provider knowledge, and busy clinic visits limiting time for informed consent and maintaining patient autonomy for genetic testing. Although heterogeneous, the literature supports multimedia use in cancer genetics. However, there is a paucity of data in the field of gynecologic oncology for the role of integrating a multimedia approach to genetic counseling.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
6mo left

Started Oct 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress77%
Oct 2024Oct 2026

Study Start

First participant enrolled

October 10, 2024

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

July 16, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 24, 2025

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2026

Last Updated

November 12, 2025

Status Verified

November 1, 2025

Enrollment Period

2.1 years

First QC Date

July 16, 2025

Last Update Submit

November 10, 2025

Conditions

Keywords

genetic testingvideo implementationchart review

Outcome Measures

Primary Outcomes (1)

  • Proportion of genetic testing

    Proportion of eligible patients undergoing any genetic testing before and after the implementation of educational videos.

    Baseline

Secondary Outcomes (2)

  • Overall rates of genetic testing

    Baseline

  • Patient satisfaction

    Baseline

Study Arms (1)

Genetic Testing Awarness

EXPERIMENTAL

Educational videos about genetic testing will be provided for ovarian cancer and endometrial cancer.

Behavioral: Educational videosBehavioral: Survey

Interventions

Educational videos about genetic testing will be provided. Subjects will be asked to view one of three videos (an endometrial cancer/Lynch Syndrome video or a longer or shorter version of an ovarian cancer video) relevant to their cancer diagnosis and genetic testing.

Also known as: Genetic testing information
Genetic Testing Awarness
SurveyBEHAVIORAL

Subjects will be asked to complete a brief satisfaction survey.

Genetic Testing Awarness

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • In order to participate in this study, a subject must meet all of the eligibility criteria outlined below.
  • Reviewed informed consent to participate in the study.
  • Subject is willing and able to comply with study procedures based on the judgment of the investigator.
  • Age ≥ 18 years at the time of consent.
  • Diagnosis of ovarian cancer or endometrial cancer
  • Eligible for genetic testing
  • English or Spanish is the primary language

You may not qualify if:

  • Previously completed genetic testing
  • Did not receive initial cancer-directed treatment at study site

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Univeristy of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Ovarian NeoplasmsEndometrial Neoplasms

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal DisordersUterine NeoplasmsUterine Diseases

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Katherine Tucker, MD

    UNC Lineberger Comprehensive Cancer Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 16, 2025

First Posted

July 24, 2025

Study Start

October 10, 2024

Primary Completion (Estimated)

October 30, 2026

Study Completion (Estimated)

October 30, 2026

Last Updated

November 12, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations